Malkit Riyat, MBChB, MRCPath, FRCPath
Dr. Malkit Riyat completed his MBChB degree from the University of Nairobi in 1978 and underwent a World Health Organization (WHO) fellowship in Hematology from the Royal Infirmary, Glasgow in 1987. He was appointed as a Fellow of the Royal College of Pathologist in Hematology in 1997.
Owing to his unique training in both laboratory and clinical hematology, Dr. Riyat can perform hematological investigations, analyze and interpret blood and bone marrow samples to arrive at a diagnosis and treat patients with a variety of blood disorders/cancers. In 2002 he initiated and was responsible for the successful coordination and implementation of the now nationally prominent GLIVEC international patient assistance program (GIPAP) in Kenya. Dr. Riyat, due to his expertise in the field of blood transfusion, was appointed a core member of the team to develop a national policy on the guidelines for the appropriate use of blood and blood related products by the Ministry of Health, Kenya. Dr. Riyat’s current research interests include molecular biology and targeted therapy of hematological malignancies, hematological manifestations of HIV infections and the role of bone marrow microenvironment in multiple myeloma.
Kasmani R, Othieno-Abinya NA, Riyat MS, Kiarie GW, Wanzala P. Environmental and occupational factors associated with chronic myeloid leukemia: a case-control study J. Afr Cancer 2014; 6(4):194-201.
Kiraka G, Etabale M, Riyat MS A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya J. Afr. Cancer (2014) 6:70-74
E. Mulwa-Babu, D. Paresh, Riyat MS. Applying consensus criteria to the evaluation of patients with suspected chronic lymphocytic leukemia/small lymphocytic lymphoma. J. Afr Cancer 2014; 6(4):215-217.
Kasmani R, Othieno-Abinya NA, Riyat MS, Kiarie GW, Wanzala P Environmental and occupational factors associated with chronic myeloid leukemia: a case-control study. J. Afr Cancer 2014; 6(4):194-201.
BSc, MBChB, MRCP, FRCPath
Dr. Mwirigi graduated with a MBChB degree from the University of Glasgow in 2002, having also a pursued an intercalated degree earning her Bsc (MedSci) in 2000 from the same university. After 4 years of Internal Medicine training in Glasgow and gaining Membership of the Royal College of Physicians in 2007, she commenced her career in Hematology as a Senior House Officer at King’s College Hospital. She thereafter became a Specialist Registrar at Guy’s and St Thomas’ NHS Trust in 2009 and a Fellow of the Royal College of Pathologist in Hematology in 2012. She obtained her Certificate of Completion of Training (CCT) in 2014, and later took up consultant position for a period of two and a half years at both Guy’s and St Thomas’ and King’s College Hospitals. Dr. Mwirigi was recently a sub-investigator in the MEDALIST 2016 trial looking at the efficacy of luspatercept, a novel drug, in patients with myelodysplastic syndrome with ring sideroblasts who require blood transfusions. Dr. Mwirigi is an active member of various local and international hematological societies
Gardner K, Douiri A, Drasar E, Allman M, Mwirigi A et al. Survival in adults with sickle cell disease in a high-income setting. Blood 2016; 128(10):1436-8 DOI 10.1182/blood-2016-05-716910.
Mwirigi A., Hunt BJ. Re: Length of stay after Hip Fracture and short-term risk of death after discharge: a total cohort study in Sweden. BMJ 2015; 350:h696.
Mwirigi, A et al. Is there benefit in extensive screening for cancer in patients with unprovoked venous thromboembolism? Thromb. Res. Dec 2015; 136(6); 1332-1333.